| Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses -> Monitor Keywords |
|
|
  Dihydro-1,3,5-triazine amine derivatives and their therapeutic usesUSPTO Application #: 20080108591Title: Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses Abstract: These compounds can be used in the treatment of pathological conditions associated with the insulin-resistance syndrome. in which R1, R2, R3, R4, R5 and R6 are as defined in claim 1. The invention relates to the compounds of general formula (I): (end of abstract) Agent: Young & Thompson - Alexandria, VA, US Inventors: Gerard Moinet, Daniel Cravo, Liliane Doare, Micheline Kergoat, Didier Mesangeau USPTO Applicaton #: 20080108591 - Class: 514173000 (USPTO) Related Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Cyclopentanohydrophenanthrene Ring System Doai, Hetero Ring Containing, Spiro Ring System The Patent Description & Claims data below is from USPTO Patent Application 20080108591. Brief Patent Description - Full Patent Description - Patent Application Claims
[0001] The present invention relates to amine-containing derivatives of dihydro-1,3,5-triazine which are useful in the treatment of pathological conditions associated with the insulin-resistance syndrome. [0002] Amine-containing derivatives of dihydro-1,3,5-triazine having hypoglycaemic properties have been described in JP-A-73 64 088 and JP-A-79 14 986. [0003] The aim of the present invention is to provide novel compounds having improved properties. [0004] The subject of the present invention is thus a compound of general formula (I): in which: R1, R2, R3 and R4 are chosen independently from the groups: [0005] H, [0006] (C1-C20)alkyl substituted or otherwise with halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C3-C8)cycloalkyl, [0007] (C2-C20)alkylene substituted or otherwise with halogen, (C1-C5)alkyl, (C1-C5)alkoxy, [0008] (C2-C20)alkyne substituted or otherwise with halogen, (C1-C5)alkyl, (C1-C5)alkoxy, [0009] (C3-C8)cycloalkyl substituted or otherwise with (C1-C5)alkyl, (C1-C5)alkoxy, [0010] (C3-C8)heterocycloalkyl carrying one or more heteroatoms chosen from N, O, S and substituted or otherwise with (C1-C5)alkyl, (C1-C5)alkoxy, [0011] (C6-C14)aryl(C1-C20)alkyl substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl-(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0012] (C6-C14)aryl substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0013] (C1-C13)heteroaryl carrying one or more heteroatoms chosen from N, O, S and substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl-(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0014] it being possible for R1 and R2, on the one hand, and R3 and R4, on the other hand, to form with the nitrogen atom an n-membered ring (n between 3 and 8) comprising or otherwise one or more heteroatoms chosen from N, O, S and being capable of being substituted with one or more of the following groups: amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, R5 and R6 are chosen independently from the groups: [0015] H, [0016] (C1-C20)alkyl substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0017] (C2-C20)alkylene substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0018] (C2-C20)alkyne substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0019] (C3-C8)cycloalkyl substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxy-ethyl, [0020] (C3-C8)heterocycloalkyl carrying one or more heteroatoms chosen from N, O, S and substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl-(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0021] (C6-C14)aryl substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0022] (C1-C13)heteroaryl carrying one or more heteroatoms chosen from N, O, S and substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl-(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0023] (C6-C14)aryl(C1-C5)alkyl substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl-(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0024] it being possible for R5 and R6 to form with the carbon atom to which they are attached an m-membered ring (m between 3 and 8) comprising or otherwise one or more heteroatoms chosen from N, O, S and being capable of being substituted with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0025] or being capable of forming with the carbon atom a C10-C30 polycyclic residue substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, [0026] it being possible for the nitrogen atom of a hetero-cycloalkyl or heteroaryl group to be substituted with a (C1-C5)alkyl, (C3-C8)cycloalkyl, (C6-C14)aryl, (C6-C14)aryl(C1-C5)alkyl or (C1-C6)acyl group, with the exclusion of the compounds of formula I in which: [0027] a--R1=H, R2=H, R3=H, R5=CH3, R6=CH3 and R4=phenethyl, phenoxyethyl, 2-phenylthioisopropyl or benzyl; [0028] b--R1=H, R2=H, R3=H or CH3, R4=H, methyl, butyl or phenethyl, R5=H or ethyl and R6 is 3-methyl-5-isoxazolyl, 5-methyl-3-isoxazolyl, 3-methyl-5-pyrazolyl or (5-methyl-3-isoxazolyl)methyl, [0029] c--R1, R2, R3 and R4 represent a hydrogen atom, as well as the tautomeric, enantiomeric, diastereo-isomeric and epimeric forms and the pharmaceutically acceptable salts. [0030] The expression m-membered ring formed by R5 and R6 is understood to mean in particular a saturated ring such as a cyclohexyl, piperidinyl or tetrahydropyranyl group. [0031] The expression polycyclic group formed by R5 and R6 is understood to mean an optionally substituted carbon-containing polycyclic group and in particular a steroid residue. [0032] A particular group of compounds of formula (I) is that in which R5 is hydrogen. [0033] Another particular group of compounds of formula (I) is that in which R5 and R6 form with the carbon atom to which they are attached an m-membered ring (m between 3 and 8) comprising or otherwise one or more heteroatoms chosen from N, O, S and being capable of being substituted with one or more of the following groups: (C1-C5)alkyl, amino, hydroxyl, (C1-C5)alkyl-amino, (C1-C5)alkoxy, (C1-C5)alkylthio, (C6-C14)aryl, (C6-C14)aryl(C1-C5)alkoxy, [0034] or form with the carbon atom a C10-C30 poly-cyclic residue substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl. [0035] Another particular group of compounds of formula (I) is that in which R5 and R6 are chosen independently from the groups: [0036] (C1-C20)alkyl substituted or otherwise with amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl. [0037] A more particular group of compounds of formula (I) is that in which R1 and R2 are chosen independently from the groups specified above with the exception of the hydrogen atom and R3 and R4 represent a hydrogen. More particularly, a preferred group of compounds of formula (I) is that in which R1 and R2 are an alkyl, advantageously methyl, group and R3 and R4 represent a hydrogen. [0038] The invention also relates to the tautomeric, enantiomeric, diastereoisomeric and epimeric forms of the compounds of general formula (I). [0039] The compounds of general formula (I) possess basic nitrogen atoms which may be monosalified or disalified with organic or inorganic acids. [0040] The compounds of general formula (I) may be prepared by reacting a compound of general formula (II) in which R1, R2, R3 and R4 are as defined above, with a compound of general formula (III), (IV) or (V) in which R5 and R6 are as defined above and R7 is a methyl or ethyl group, in a polar solvent (for example ethanol or dimethylformamide) in the presence of an organic acid (for example camphorsulphonic acid) or of an inorganic acid (for example hydrochloric acid). Continue reading... Full patent description for Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses patent application. Patent Applications in related categories: 20080207576 - Substituted sapogenins and their use - The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed ... ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses or other areas of interest. ### Previous Patent Application: Pharmaceutical composition Next Patent Application: New method Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses patent info. IP-related news and info Results in 0.66909 seconds Other interesting Feshpatents.com categories: Software: Finance , AI , Databases , Development , Document , Navigation , Error |
||
